ATP128 + ezabenlimab

ATP128 + ezabenlimab is a combination investigational therapy composed of a novel cancer vaccine (ATP128) and a monoclonal antibody checkpoint inhibitor (ezabenlimab). **ATP128** is a self-adjuvanted chimeric recombinant protein vaccine designed to stimulate the immune system against tumor-associated antigens; it incorporates cell-penetrating peptides for antigen delivery, a Toll-like receptor agonist domain with self-adjuvant properties, and a multi-antigenic domain targeting carcinoembryonic antigen (CEA), survivin, and achaete-scute complex homolog 2 (ASCL2)[3][1]. **Ezabenlimab** (BI 754091) is a humanized IgG4 monoclonal antibody directed against programmed cell death protein 1 (PD-1), functioning as a checkpoint inhibitor to enhance T-cell mediated anti-tumor responses[2][1]. The combination is being investigated for **stage IV colorectal cancer**, particularly in microsatellite stable (MSS) and mismatch repair-proficient types, and has demonstrated induction of antigen-specific immune responses, increased CD8+ T cell infiltration, reduction in T cell exhaustion markers, and overall tolerability in early clinical studies[1][3][5].

Other names

ATP128 + BI 754091ATP128 + ezabenlimab